Senaste nyheterna 15 November 2023Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial beginsGedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins 8 November 2023Gedea Biotech receives approval to initiate the pivotal NEFERTITI-2 clinical study documenting the performance of pHyph for treatment of bacterial vaginosisLund, Sweden, November 8, 2023. Swedish women’s health company Gedea Biotech developing antibiotic-free treatments, today announced that the Swedish… 13 September 2023Gedea Biotech granted European Patent for the formulation of its vaginal pHyph tablet for women with vaginal infectionsSwedish women’s health company Gedea Biotech announced today that the European Patent Office (EPO) has granted the company´s patent application no.… 21 June 2023Making a difference to women worldwideGedea Biotech has developed the world’s first antibiotic-free treatment to both treat and prevent bacterial vaginosis. The treatment is called pHyph,… 24 May 2023Gedea Biotech secures 1.3 MEuros (14 MSEK) to advance its antibiotic-free vaginal infection treatment pHyph towards market launchLund, Sweden, May 24, 2023: Gedea Biotech today announced that it has raised 1.3 MEuros (14 MSEK) for additional development activities of their… 2 May 2023Gedea Biotech initiates EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal CandidiasisLund, Sweden, May 2, 2023. Gedea Biotech today announces that the treatment of the first patients with its lead product, pHyph, a vaginal tablet for… Press kitKlicka för att ladda ner logotyper och bilder
